Journal
CURRENT OPINION IN VIROLOGY
Volume 17, Issue -, Pages 57-65Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2016.01.007
Keywords
-
Categories
Funding
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-11-2-0174]
- NIH NIAID award [UM1AI068635]
- U.S. Department of Defense (DOD) [W81XWH-11-2-0174]
Ask authors/readers for more resources
Phase IIb or III HIV-1 vaccine efficacy trials are generally large and operationally challenging. To mitigate this challenge, the HIV Vaccine Trials Network is designing a Phase IIb efficacy trial accommodating the evaluation of multiple vaccine regimens concurrently. As this efficacy trial would evaluate a limited number of vaccine regimens, there is a need to develop a framework for optimizing the strategic selection of regimens from the large number of vaccine candidates tested in Phase I/IIa trials. In this paper we describe the approaches for the selection process, including the choice of immune response endpoints and the statistical criteria and algorithms. We illustrate the selection approaches using data from HIV-1 vaccine trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available